Bluebird Bio Sells Itself to Investment Firms for $30 Million
Bluebird Bio, facing bankruptcy, has agreed to sell itself to investment firms Carlyle and SK Capital for less than $30 million. The deal will allow the company to avoid financial ruin. Shareholders can expect to receive $3 per share initially, with an additional potential gain of $6.87 per share if the company’s gene therapies become … Read more